Julien Bradley

Chief Executive Officer @Axion BioSystems

Boston, MA, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Oct 2023 — Present

Chief Executive Officer @Axion BioSystems

View department →

Atlanta, GA, US

Supporting the global research community with tools that better reflect complex biology.Leading Axion’s mission to advance human-relevant, real-time biological insights.Guiding innovation at the intersection of biology, technology, and translational research.

EDUCATION

1994 — 1998

Amherst College

BA, Biology & German

1998 — 1999

University of Vermont

M.Ed, Secondary Education

2003 — 2005

The Tuck School of Business at Dartmouth

Master of Business Administration (MBA), Tuck Scholar, Business Administration and Management, General

SKILLS

EntrepreneurshipBiotechnologyStrategyKey Account ManagementProduct LaunchMarket ResearchMedical DevicesInternational BusinessMarketingManagementChannel PartnersBusiness DevelopmentCross-Functional Team LeadershipMarketing StrategyPharmaceutical IndustryBusiness PlanningProduct MarketingSales OperationsCommercializationLifesciencesProgram ManagementSalesMarket AnalysisCompetitive AnalysisStart-UpsLeadershipR&DSales ManagementMarket DevelopmentStrategic PlanningProduct ManagementNew Business DevelopmentResearchMarket PlanningLife SciencesInternational SalesBusiness StrategyStrategic PartnershipsProject ManagementProduct Development

ABOUT JULIEN BRADLEY

I am a life sciences executive with a career focused on building, scaling, and leading technology-drivenorganizations at the intersection of biology, data, and decision-making.As Chief Executive Officer of Axion BioSystems, I lead the company’s efforts to support researchers andinnovators seeking deeper, more physiologically relevant insight into complex biological systems. Axion’splatforms enable real-time, label-free functional analysis that is increasingly critical for neuroscience,cardiac research, organoids, and advanced cell models.Throughout my career, I have been drawn to technologies that change how science is practiced, notincrementally, but fundamentally, by improving the quality, relevance, and translational value of biologicaldata. I am particularly interested in how functional assays, automation, and new biological models arereshaping discovery workflows across academia and industry.I use this platform to engage with scientists, leaders, and innovators on where life science research isheaded and how we can collectively accelerate meaningful progress.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.